Clinical trial
Phase 2 Study of Ribociclib-Containing Post-Radiotherapy Combinations in Pediatric and Young Adult Patients Newly Diagnosed With High-Grade Glioma, Including Diffuse Intrinsic Pontine Glioma: Ribociclib and Everolimus for HGG/DIPG Which Harbor Alterations of the Cell Cycle and/or PI3K/mTOR Pathways AND Ribociclib and Temozolomide for DHG, H3G34-mutant
NCT05843253 is registered in ClinicalTrials.gov with Nationwide Children's Hospital as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Phase 2 Study of Ribociclib-Containing Post-Radiotherapy Combinations in Pediatric and Young Adult Patients Newly Diagnosed With High-Grade Glioma, Including Diffuse Intrinsic Pontine Glioma: Ribociclib and Everolimus for HGG/DIPG Which Harbor Alterations of the Cell Cycle and/or PI3K/mTOR Pathways AND Ribociclib and Temozolomide for DHG, H3G34-mutant
- Lead sponsor
- Nationwide Children's Hospital
- Phase
- Phase 2
- Overall status
- Recruiting
- Start date
- August 22, 2024
- Completion date
- August 28, 2034
- Enrollment
- 120 (estimated)
- Sites
- 20
Conditions
As the registry lists them; a condition with its own page is linked.
anaplastic astrocytoma, diffuse hemispheric glioma, h3 g34-mutant, diffuse intrinsic pontine glioma, diffuse midline glioma, h3 k27m-mutant, glioblastoma, glioblastoma multiforme, high grade glioma, metastatic brain tumor, who grade iii glioma, who grade iv glioma